TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 2572036
Drug: Salbutamol (oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salbutamol (oral route, total dose 26 mg)
Study: 2572036
Drug: Salbutamol (inhaled
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salbutamol (inhaled route, total dose 1.5 mg)
Study: 2572036
Drug: Broxaterol (oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Broxaterol (oral route)
Study: 2572036
Drug: Broxaterol (inhaled
Approvals — FDA: no, EMA: no, PMDA: no
Description: Broxaterol (inhaled route)
Study: 31843335
Drug: Abiraterone acetate
Normalized name: ABIRATERONE ACETATE
DrugBank: Abiraterone (DB05812)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Abiraterone acetate plus androgen deprivation therapy (AAP + ADT)
Study: 31843335
Drug: Placebo plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo plus androgen deprivation therapy (PBO + ADT)
Study: 28121978
Drug: Topical Lidocaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical Lidocaine cream (TL)
Study: 27561376
Drug: Rivastigmine patch
Normalized name: Rivastigmine
DrugBank: Rivastigmine (DB00989)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Rivastigmine patch (applied from 3 days before to 7 days after surgery)
Study: 27561376
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no rivastigmine patch)
Study: 21645184
Drug: Rivastigmine patch
Normalized name: Rivastigmine
DrugBank: Rivastigmine (DB00989)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Rivastigmine patch
Study: 18397386
Drug: Ribavirin 800
Normalized name: ribavirin 800 Dose Pack, 4 Unit Dose Packs, 14 Tablets Each
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ribavirin 800 mg/day
Study: 18397386
Drug: Ribavirin 1000/1200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ribavirin 1000/1200 mg/day
Study: 12669750
Drug: Preparation time
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preparation time in go trials
Study: 11127213
Drug: HRT (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: HRT (2 mg of estradiol valerate and 1 mg of cyproterone acetate with or without vitamin D3, 100-300 IU + 93 mg calcium as lactate per day)
Study: 11127213
Drug: Non-HRT (93
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-HRT (93 mg of calcium alone or in combination with vitamin D3, 100-300 IU/day)
Study: 9192993
Drug: Prophylactic intracavitary
Normalized name: polylactic acid-polyglycolic acid copolymer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prophylactic intracavitary treatment with interferon alpha 2b (IFN‐alpha‐2b)
Study: 22256639
Drug: Auricular point
Normalized name: ActivOn Joint & Muscle
Approvals — FDA: no, EMA: no, PMDA: no
Description: Auricular point sticking therapy
Study: 23140031
Drug: Rectal Balloon
Normalized name: CATHETER,BALLOON
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rectal Balloon Training (RBT)
Study: 18537189
Drug: Entecavir 1
Normalized name: entecavir 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Entecavir 1 mg
Study: 17983800
Drug: Lamivudine 100
Normalized name: lamivudine 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lamivudine 100 mg
Study: 7720152
Drug: Low-dose midazolam
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose midazolam (0.03 mg.kg-1)
Study: 7720152
Drug: High-dose midazolam
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose midazolam (0.06 mg.kg-1)
Study: 6103906
Drug: Fenoterol hydrobromide,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fenoterol hydrobromide, 1 mg/ml, nasal spray (204 to 576 microgram)
Study: 25542917
Drug: Taste receptor
Normalized name: 60 Second Taste
Approvals — FDA: no, EMA: no, PMDA: no
Description: Taste receptor genotype
Study: 23576518
Drug: Cognitive-behavioural therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-behavioural therapy (CBT) group intervention, 8 weeks duration
Study: 18334911
Drug: Haloperidol 15
Normalized name: haloperidol 150 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Haloperidol 15 mg/d
Study: 14709949
Drug: Thioridazine 300
Normalized name: Thioridazine
DrugBank: Thioridazine (DB00679)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Thioridazine 300 mg/d
Study: 14709949
Drug: Quetiapine 750
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quetiapine 750 mg/d
Study: 19440083
Drug: Olanzapine 20
Normalized name: olanzapine 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olanzapine 20 mg/d
Study: 14709949
Drug: Risperidone 6-8
Normalized name: risperidone 6 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Risperidone 6-8 mg/d increased to 16 mg/d
Study: 14709949
Drug: Metabolic inhibition
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metabolic inhibition (concomitant administration of CYP450 inhibitors)
Study: 2961818
Drug: Plasma-derived vaccine
Normalized name: Haptoglobulin 1/1 (Plasma Derived)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Plasma-derived vaccine (40-micrograms dose)
Study: 2961818
Drug: Recombinant-derived vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recombinant-derived vaccine (40-micrograms and 20-micrograms doses)
Study: 26258145
Drug: Ramosetron 0.6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ramosetron 0.6 mg (group C)
Study: 26258145
Drug: Ramosetron 0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ramosetron 0.3 mg (group A)
Study: 9387643
Drug: Intravenous cyclophosphamide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous cyclophosphamide pulse therapy every 2 weeks (15 mg/kg per pulse)
Study: 9387643
Drug: Intravenous cyclophosphamide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous cyclophosphamide pulse therapy every 4 weeks (15 mg/kg per pulse)
Study: 6374280
Drug: Nifedipine 40
Normalized name: nifedipine 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nifedipine 40 mg oral dose
Study: 6374280
Drug: Nifedipine 40
Normalized name: nifedipine 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nifedipine 40 mg oral dose with standard breakfast
Study: 25390695
Drug: Levosimendan (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levosimendan (25 hours infusion)
Study: 23075178
Drug: Ustekinumab 1
Normalized name: ustekinumab 130 MG in 26 ML Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ustekinumab 1 mg/kg
Study: 23075178
Drug: Ustekinumab 3
Normalized name: Ustekinumab
DrugBank: Ustekinumab (DB05679)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Ustekinumab 3 mg/kg
Study: 29726939
Drug: Ustekinumab 6
Normalized name: Ustekinumab
DrugBank: Ustekinumab (DB05679)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Ustekinumab 6 mg/kg
Study: 23075178
Drug: Ustekinumab (maintenance)
Normalized name: Ustekinumab
DrugBank: Ustekinumab (DB05679)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Ustekinumab (maintenance) 90 mg
Study: 20156909
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of medroxyprogesterone (500 mg/day) or megestrol acetate (320 mg/day), oral supplementation with eicosapentaenoic acid, L-carnitine (4 g/day), thalidomide (200 mg/day)
Study: 20156909
Drug: Thalidomide (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thalidomide (200 mg/day)
Study: 20156909
Drug: L-carnitine (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-carnitine (4 g/day)
Study: 20156909
Drug: Oral supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral supplementation with eicosapentaenoic acid
Study: 20156909
Drug: Medroxyprogesterone (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medroxyprogesterone (500 mg/day) or Megestrol acetate (320 mg/day)
Study: 17360171
Drug: Zileuton 600
Normalized name: zileuton 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zileuton 600 mg QID + 200 microg beclomethasone dipropionate (BDP) BID
Study: 17360171
Drug: Zileuton 400
Normalized name: Zileuton
DrugBank: Zileuton (DB00744)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Zileuton 400 mg QID + 200 microg beclomethasone dipropionate (BDP) BID
Study: 16352931
Drug: Goserelin (GOS)
DrugBank: Goserelin (DB00014)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Goserelin (GOS) 3.6 mg/4 weeks for 2 years
Study: 7666098
Drug: Standard CHOP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard CHOP (full doses every 3 weeks)
Study: 7666098
Drug: Weekly CHOP
Normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Weekly CHOP (one-third doses weekly)
Study: 7666098
Drug: Weekly CHOP
Normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Weekly CHOP
Study: 2540245
Drug: S-ACV (daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: S-ACV (daily suppressive oral acyclovir)
Study: 23234420
Drug: Oral random
Normalized name: jojoba oil, randomized
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral random generation (secondary task loading executive functions)
Study: 16525576
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg oral aspirin for 5 days
Study: 16525576
Drug: 325 mg
Normalized name: lysine 325 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 325 mg oral aspirin for 5 days
Study: 16525576
Drug: In vitro
Normalized name: glucuronidase in vitro test
Approvals — FDA: no, EMA: no, PMDA: no
Description: In vitro aspirin (150 micromol/l)
Study: 16525576
Drug: NS398 (COX-2
Approvals — FDA: no, EMA: no, PMDA: no
Description: NS398 (COX-2 inhibitor)
Study: 16525576
Drug: SB203580 (p38-MAPK
Approvals — FDA: no, EMA: no, PMDA: no
Description: SB203580 (p38-MAPK inhibitor)
Study: 11115036
Drug: 150 mL/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 mL/kg per day
Study: 11115036
Drug: 200 mL/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mL/kg per day
Study: 3490803
Drug: Propofol (2.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propofol (2.2 mg kg‐1 body weight, reduced to 1.8 mg kg‐1 with opioids and benzodiazepins)
Study: 29248753
Drug: Vitamin D
Normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D (300000 Unit, single intramuscular injection)
Study: 26689781
Drug: Intrathecal morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intrathecal morphine (ITM) 300 µg and intravenous patient-controlled analgesia (IV-PCA)
Study: 19889470
Drug: Mosapride citrate
Normalized name: mosapride citrate
DrugBank: Mosapride (DB11675)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mosapride citrate (15 mg/day)
Study: 18794551
Drug: Exemestane 25
Normalized name: exemestane 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exemestane 25 mg orally once daily
Study: 18794551
Drug: Tamoxifen 20
Normalized name: tamoxifen 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tamoxifen 20 mg orally once daily
Study: 15983794
Drug: D1/D2 receptor
Approvals — FDA: no, EMA: no, PMDA: no
Description: D1/D2 receptor stimulation under TPD conditions (using pergolide)
Study: 7726426
Drug: Epidural clonidine
Normalized name: Clonidine
DrugBank: Clonidine (DB00575)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Epidural clonidine 4 micrograms/kg + morphine 2 mg (Group CM)
Study: 7726426
Drug: Epidural morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural morphine 50 micrograms/kg (Group M)
Study: 2285385
Drug: Himega (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Himega (2 g/day or 4 g/day of n‐3 fatty acid)
Study: 2285385
Drug: Triglyceride-based fish
Normalized name: CAPRYLIC TRIGLYCERIDE
DrugBank: Tricaprylin (DB12176)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triglyceride-based fish oil (2 g/day or 4 g/day of n‐3 fatty acid)
Study: 2285385
Drug: Himega (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Himega (2 g/day of n‐3 fatty acid)
Study: 15251034
Drug: Fluvoxamine (75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluvoxamine (75 mg BID)
Study: 11878519
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of controlled hypotension (CH) and acute normovolaemic haemodilution (ANH) (post‐ANH haematocrit 29%; intraoperative MAP 50 mm Hg)
Study: 19773371
Drug: Sorafenib 400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sorafenib 400 mg b.i.d.
Study: 20089558
Drug: Sorafenib 400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sorafenib 400 mg b.i.d. in sarcopenic patients with BMI < 25 kg/m²
Study: 20089558
Drug: Sorafenib 400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sorafenib 400 mg b.i.d. in non-sarcopenic patients and/or overweight or obese
Study: 20089558
Drug: Sorafenib 800
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sorafenib 800 mg/day in sarcopenic male patients with BMI < 25 kg/m²
Study: 20089558
Drug: Sorafenib 800
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sorafenib 800 mg/day in male patients above the cut-off for sarcopenia
Study: 20089558
Drug: Sorafenib 800
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sorafenib 800 mg/day in male patients with BMI > 25
Study: 18715214
Drug: Sensor group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sensor group (SG) - pump therapy with real-time continuous glucose monitoring (CGM)
Study: 18715214
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (CG) - pump therapy and self-monitoring of blood glucose only
Study: 15757423
Drug: Benazepril plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Benazepril plus amlodipine (40/10 mg)
Study: 15757423
Drug: Benazepril plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Benazepril plus hydrochlorothiazide (40/25 mg)
Study: 8874241
Drug: Dornase alfa
Normalized name: Dornase Alfa
DrugBank: Dornase alfa (DB00003)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dornase alfa (2.5 mg once daily)
Study: 31902864
Drug: Tryptophan, vitamin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tryptophan, vitamin B6, and nicotinamide-containing supplements
Study: 30081500
Drug: Fluoxetine +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoxetine + Magnesium (120 mg/day as magnesium aspartate)
Study: 30081500
Drug: Fluoxetine +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoxetine + Magnesium
Study: 17785038
Drug: Continuous combined
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous combined hormone replacement therapy (ccHRT) with estradiol valerate (E2V) and medroxyprogesterone acetate (MPA)
Study: 12482211
Drug: Donepezil (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Donepezil (5 mg per os, evening assumption)
Study: 12482211
Drug: Propranolol (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol (40 mg bid per os)
Study: 7726479
Drug: Cefotiam Hexetil
Normalized name: Cefotiam hexetil hydrochloride
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefotiam Hexetil (CTM) 200 mg bid
Study: 7726479
Drug: Cefixime (CX)
Normalized name: Cefixime
DrugBank: Cefixime (DB00671)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cefixime (CX) 200 mg bid
Study: 15195032
Drug: Serenoa repens
Normalized name: Serenoa Repens Fruit
DrugBank: Saw palmetto (DB14360)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Serenoa repens (320 mg/die of Permixon) for at least 8 weeks before TURP
Study: 15195032
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no medical treatment before intervention)
Study: 2601868
Drug: 1 g
Normalized name: Molds 1 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 g of naproxene + 2 g of rosaprostol
Study: 2601868
Drug: 1 g
Normalized name: Molds 1 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 g of naproxene + placebo
Study: 29020783
Drug: Corifollitropin alfa
Normalized name: corifollitropin alfa
DrugBank: Corifollitropin alfa (DB09066)
Approvals — FDA: no, EMA: yes, PMDA: no
Description: Corifollitropin alfa (Elonva) 100 µg for women younger than 36 years and less than 60 kg; 150 µg for women older than 36 years or heavier than 60 kg, combined with GnRH antagonists.
Study: 29020783
Drug: Corifollitropin alfa
Normalized name: corifollitropin alfa
DrugBank: Corifollitropin alfa (DB09066)
Approvals — FDA: no, EMA: yes, PMDA: no
Description: Corifollitropin alfa and GnRH antagonists
Study: 26162813
Drug: Group C:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group C: Same treatment as Group B but ESWT guided by musculoskeletal sonography
Study: 19210062
Drug: Repetition of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Repetition of persuasive arguments (seen once or twice)
Study: 15269144
Drug: BEC2 anti-idiotypic
Normalized name: anti-CD11a
DrugBank: Efalizumab (DB00095)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: BEC2 anti-idiotypic monoclonal antibody vaccine (25-microg dose)
Study: 15269144
Drug: GD3-lactone-KLH (GD3-L-KLH)
Normalized name: Irinotecan lactone
DrugBank: Irinotecan (DB00762)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: GD3-lactone-KLH (GD3-L-KLH) vaccine
Study: 15269144
Drug: Overall immunization
Normalized name: Immune Globulin
DrugBank: Human immunoglobulin G (DB00028)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Overall immunization with either vaccine
Study: 15269144
Drug: GD3-L-KLH vaccine
Normalized name: L
Approvals — FDA: no, EMA: no, PMDA: no
Description: GD3-L-KLH vaccine
Study: 15269144
Drug: BEC2 vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BEC2 vaccine
Study: 7962344
Drug: 2 mg
Normalized name: iodine 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg 17 beta‐estradiol combined with 2.5 mg dydrogesterone
Study: 7962344
Drug: 2 mg
Normalized name: iodine 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg 17 beta‐estradiol combined with 5 mg dydrogesterone
Study: 7962344
Drug: 2 mg
Normalized name: iodine 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg 17 beta‐estradiol combined with 10 mg dydrogesterone
Study: 7962344
Drug: 2 mg
Normalized name: iodine 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg 17 beta‐estradiol combined with 15 mg dydrogesterone
Study: 7962344
Drug: 2 mg
Normalized name: iodine 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg 17 beta‐estradiol combined with all doses of dydrogesterone
Study: 28129748
Drug: Faster rate
Normalized name: diphenhydramine
DrugBank: Diphenhydramine (DB01075)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Faster rate of increase in milk feeds (30 ml/kg/day)
Study: 28129748
Drug: Slower rate
Normalized name: flowers
Approvals — FDA: no, EMA: no, PMDA: no
Description: Slower rate of increase in milk feeds (18 ml/kg/day)
Study: 25930719
Drug: Upfront zoledronic
Normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Upfront zoledronic acid (ZA) 4 mg IV every 6 months
Study: 25930719
Drug: Delayed zoledronic
Normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Delayed zoledronic acid (ZA) 4 mg IV every 6 months
Study: 22268726
Drug: Control (contralateral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (contralateral arm without treatment)
Study: 14520284
Drug: 0.25 mg
Normalized name: biotin 0.25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.25 mg of flunitrazepam (F0.25 group)
Study: 14520284
Drug: 0.5 mg
Normalized name: biotin 0.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mg of flunitrazepam (F0.5 group)
Study: 11031393
Drug: Valacyclovir hydrochloride
Normalized name: Valacyclovir Hydrochloride
DrugBank: Valaciclovir (DB00577)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Valacyclovir hydrochloride (1 g 3 times daily) for 7 days
Study: 11031393
Drug: Famciclovir (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Famciclovir (500 mg 3 times daily) for 7 days
Study: 31288820
Drug: liraglutide (1.8
Approvals — FDA: no, EMA: no, PMDA: no
Description: liraglutide (1.8 mg/day)
Study: 24783469
Drug: Continuous positive
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous positive airway pressure therapy (CPAP) for 24 weeks
Study: 22722504
Drug: ziprasidone 40
Normalized name: ziprasidone 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: ziprasidone 40 to 80 mg/d
Study: 22722504
Drug: ziprasidone 120
Approvals — FDA: no, EMA: no, PMDA: no
Description: ziprasidone 120 to 160 mg/d
Study: 22722504
Drug: ziprasidone 40
Normalized name: ziprasidone 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: ziprasidone 40 to 160 mg/d
Study: 12053117
Drug: Observed Tasks
Normalized name: MASK
DrugBank: Benzoyl peroxide (DB09096)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Observed Tasks of Daily Living
Study: 9469359
Drug: BEP/EP chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: BEP/EP chemotherapy regimen (bleomycin, etoposide, and cisplatin)
Study: 9469359
Drug: BOP/VIP-B chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: BOP/VIP-B chemotherapy regimen (bleomycin, vincristine, cisplatin / etoposide, ifosfamide, cisplatin, and bleomycin)
Study: 7665441
Drug: Methylphenidate (MPH),
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methylphenidate (MPH), 10 mg single dose
Study: 778483
Drug: Small doses
Normalized name: smallpox vaccine live, New York City Board of Health vaccinia strain Injectable Solution [ACAM2000]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Small doses of s.c. heparin
Study: 28224289
Drug: Frontalis suspension
Normalized name: Bos taurus frontal lobe preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Frontalis suspension using Gore-Tex through a skin crease incision (group I)
Study: 28224289
Drug: Frontalis suspension
Normalized name: Bos taurus frontal lobe preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Frontalis suspension using Gore-Tex through supraciliary incisions (group II)
Study: 25886787
Drug: 7-Valent Pneumococcal
Normalized name: Streptococcus pneumoniae serotype 10A capsular antigen diphtheria CRM197 protein conjugate vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7-Valent Pneumococcal Conjugate Vaccine
Study: 24002213
Drug: CB formulation
Normalized name: BroveX CB
Approvals — FDA: no, EMA: no, PMDA: no
Description: CB formulation (Curcuma longa and Boswellia serrata extracts) 500 mg twice a day
Study: 21385602
Drug: Citalopram (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Citalopram (20 mg in 12 h)
Study: 18823361
Drug: Fixed combination
Normalized name: Progestogens and estrogens, fixed combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed combination of acetylsalicylic acid + paracetamol + caffeine
Study: 19472440
Drug: Pain reduction
Normalized name: reductic acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pain reduction by 50% within 1 hour after drug intake
Study: 14513922
Drug: 52 g
Normalized name: Konsyl 0.52 GM Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: 52 g tryptophan depleting amino-acid drink
Study: 11071421
Drug: ECHO36 (lemon-lime
Approvals — FDA: no, EMA: no, PMDA: no
Description: ECHO36 (lemon-lime ECHO with 36 mEq/L NaCl)
Study: 11071421
Drug: ECHO18 (lemon-lime
Approvals — FDA: no, EMA: no, PMDA: no
Description: ECHO18 (lemon-lime ECHO with 18 mEq/L NaCl)